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DLK1
+ cells in E14.5 liver contain high proliferative and bipotential hepatoblasts. While the expression of epithelial cell adhesion molecule (EpCAM) in hepatic stem/progenitor cells has been reported, its expression profile at an early stage of liver development remains unknown. In this study, we show that EpCAM is expressed in mouse liver bud at E9 
Introduction
Liver development begins at embryonic day (E) 8.5 in the mouse from the foregut endoderm. The ventral wall of the foregut endoderm faces the developing heart by approximately E8 and receives inductive signals for the hepatic fate, such as fibroblast growth factor (FGF), from the heart (Douarin, 1975; Gualdi et al., 1996; Jung et al., 1999) . Septum transversum mesenchyme (STM) also contributes to liver development from the foregut endoderm by providing bone 0925-4773/$ -see front matter Ó 2009 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mod.2009.06.939 morphogenetic protein (BMP), another factor involved in the liver specification (Rossi et al., 2001) . By these signals, pre-hepatic cells become proliferative and begin to form the liver bud. Following the formation of primary liver bud from E8.5 to E9.0, the basement membrane surrounding the liver bud is lost by E9.5, and pre-hepatic cells migrate as cords into the surrounding STM (Matsumoto et al., 2001; Sosa-Pineda et al., 2000; Zaret, 1998) . These pre-hepatic cells are also designated as hepatoblasts and a number of studies have indicated that hepatoblasts give rise to both hepatocytes and cholangiocytes, biliary epithelial cells (Germain et al., 1988; Rogler, 1997; Shiojiri, 1994; Shiojiri et al., 1991; Spagnoli et al., 1998) . As cell sorting using antibodies (Abs) is a powerful means to isolate and characterize a specific cell type, efforts have been made to search for specific cell-surface antigens on hepatoblasts. We previously reported that DLK1, also known as Pref-1, was strongly expressed in the E10.5 mouse liver bud and that DLK1 + cells isolated from E14.5 livers expressed albumin and formed colonies composed of hepatocyte and cholangiocyte lineages when cultured in the presence of hepatocyte growth factor (HGF) and epidermal growth factor (EGF) (Tanimizu et al., 2003 (Suzuki et al., 2000) . Thus, the colony-forming capacity is a criterion to evaluate hepatoblasts. They also showed that (Dabeva and Shafritz, 1993; Fausto et al., 1993; Sell, 1990; Thorgeirsson et al., 1993) . In rodents, oval cells with the ability to differentiate into both hepatocytes and cholangiocytes appear in the periportal region following hepatic injury under a condition that restricts hepatocyte proliferation (Evarts et al., 1990) . Although both oval cells in adults and hepatoblasts in embryos exhibit similar characteristics, i.e., proliferation and differentiation into hepatocytes and cholangiocytes (Shiojiri et al., 1991; Tian et al., 1997) , their origin and relationship remain unknown. Because of their common characteristics, it is possible that they exhibit common cell-surface molecules. In fact, DLK1 was shown to be expressed in a subpopulation of rat oval cells (Jensen et al., 2004; Tanimizu et al., 2004) . EpCAM is a cell-surface glycoprotein expressed on some normal as well as neoplastic epithelial cells (Armstrong and Eck, 2003; Momburg et al., 1987) . In the adult liver, it is known to be expressed on cholangiocytes, but not hepatocytes (de Boer et al., 1999) . Recently, we and another group reported that EpCAM is expressed in mouse and rat oval cells (Okabe et al., 2009; Yovchev et al., 2008) . In contrast, Dan et al. reported that multipotent progenitor cells derived from human fetal liver expressed EpCAM (Dan et al., 2006) . However, the expression profiles of EpCAM, e.g., location and developmental stages in human fetal liver are not known. Schmelzer et al. have reported that pluripotent precursors of hepatoblasts expressed EpCAM and were located in ductal plates in human fetal liver (Schmelzer et al., 2007) . However, the expression profile of EpCAM from the onset of liver organogenesis through the formation of ductal plates has not been known. In this report, we investigated the expression of EpCAM at an early stage of mouse liver development and show that EpCAM is the earliest and a transient marker for hepatoblasts during hepatogenesis. Moreover, the expression profile of EpCAM and DLK1 provides evidence for the developmental pathways of liver progenitors for not only hepatoblasts, but also extrahepatic bile ducts and mesothelium. 
2.
Results and discussion
Expression of EpCAM during mouse liver development
To investigate the expression profiles of EpCAM during mouse liver development, immunohistochemistry (IHC) using anti-EpCAM antibody (Ab) was performed. It is known that EpCAM is constitutively expressed in biliary epithelial cells in the normal adult liver (de Boer et al., 1999; Hreha et al., 1999) Because intrahepatic bile duct cells are known to develop in the periportal area in the late-gestational stage E16.5, we examined the expression of EpCAM as well as cytokeratin (CK)19, a marker for biliary epithelial cells in livers from E16.5 to neonatal stages by immunostaining. Both CK19 and EpCAM were weakly expressed as a discontinuous single-layered ring in the periportal area of E16.5 liver and their expression became stronger at E18.5 and the neonate stage when ductal plates with a partly bi-layered ring were clearly formed (Fig. 1A) . Consistent with the immunostaining result, EpCAM was highly expressed in the late-gestational stage, E17.5, and the neonate stage by real-time PCR (Fig. 1B) . Because the formation of ductal plates has not yet occurred in mid-gestational stages (Lemaigre, 2003; Shiojiri, 1997; Tanimizu et al., 2003) , it is reasonable that EpCAM expression is low around E14.5. Interestingly, however, EpCAM was expressed highly in E11.5 liver (Fig. 1B) . To investigate the expression of EpCAM at the onset of liver organogenesis, we immunostained transverse sections of E9.5 embryos with anti-EpCAM Ab and anti- While faint signals of EpCAM were detected at E11.5 (arrowheads), no significant signal of EpCAM was detected at E14.5. In E17.5 liver, some cells with an intense EpCAM signal but without DLK1 signal were observed around the portal vein (arrows). G, gut; PV, portal vein; Scale bars: 40 lm. We have previously reported that DLK1 + cells in E14.5 liver contain highly proliferative and bipotential hepatic progenitors, indicating that DLK1 is a hepatoblast marker in E14.5 liver (Tanimizu et al., 2003) . To investigate the relationship between EpCAM and DLK1, transverse sections of E10.5 embryos were immunostained with anti-DLK1 and anti-EpCAM Abs. As shown in Fig. 3A as a ductal plate (Figs. 1A and 3D ). These EpCAM + cells were negative for DLK1, as previously reported (Tanimizu et al., 2003) .
To reveal the detailed expression profiles of EpCAM and DLK1 during liver development, we performed FCM of fetal liver cells at E11.5, E12.5, E14.5 and E16.5, because it allows more sensitive and quantitative detection than IHC. FCM revealed that approximately 20% of nucleated cells in E11.5 liver were DLK1
+ cells, about half of which expressed EpCAM (Fig. 4) (Fig. 4) . To address this possibility, we performed FCM of E11.5 and E13.5 liver cells with another 40-1 Ab, which binds to unidentified cell-surface protein expressed on hepatoblasts, but not to DLK1 (data not shown). As shown in Fig. 6A Immunostaining of a sagital section of an E11.5 embryo with anti-CK19 and anti-DLK1 Abs showed that there was an extrahepatic region where DLK1 and CK19 were expressed (Fig. 7C) . The CK19 + cells in this region were also stained with Dolichos biflorus agglutinin (DBA), which selectively binds to extrahepatic bile ducts (Shiojiri, 1997) , indicating that sorted DLK1 + cells included fetal extrahepatic bile duct cells. On the other hand, cells at the mesothelial layer were also positively stained with anti-CK19 (Fig. 7C ). These cells were not stained with DBA, indicating that DLK1 + cells also include fetal mesothelial cells (Fig. 7D) . The expression of DLK1 in CK19 + cells and DBA + cells was confirmed by cytospin ( Fig. 7E-G Although the liver is a central metabolic organ in adults, it mainly functions as a hematopoietic organ in fetuses. Considering the marked change of liver function from the fetal to adult stage, it is not surprising that the characteristics of hepatoblasts and hepatocytes change during liver development. Whereas E-cadherin and Tim2 are constitutively expressed on the hepatocytic lineage throughout liver development (Nitou et al., 2002; Watanabe et al., 2007) , the expression of EpCAM and DLK1 on hepatoblasts is limited at the fetal stage. Therefore, a combination of these markers helps us understand the type of cells and the degree of differentiation. In this report, we show that EpCAM is expressed on hepatoblasts from the onset of liver organogenesis to approximately E14 and also on intrahepatic bile ducts after E16. While DLK1 was previously shown to be expressed on hepatoblasts, our results indicate that DLK1
+ cells are further subdivided into EpCAM + and EpCAM À cells at an earlier stage.
Colony formation assays strongly suggest that EpCAM
high cells are the earliest and highly proliferative hepatoblasts. Moreover, the expression of EpCAM is markedly downregulated within a short period of time (Fig. 3) . Fig. 8 summarizes the expression profiles of marker molecules on hepatic cells during mouse development deduced from these results. Recently, we reported that EpCAM + cells include potential hepatic stem cells in adult mouse liver (Okabe et al., 2009) . It is interesting to know whether EpCAM + hepatic stem/progenitor cells residing in adult liver are derived from the earliest EpCAM + hepatoblasts or not. In humans, it has been reported that the multipotent stem/progenitor cells de- rived from fetal liver express EpCAM (Dan et al., 2006; Schmelzer et al., 2006 Schmelzer et al., , 2007 . Additionally, it is also reported that approximately 95% and 50% of EpCAM + cells are hepatoblasts in human fetus and neonate, respectively. Because most of mouse hepatoblasts do not express EpCAM at a later gestational stage as described above, it is likely that the characteristics of hepatoblasts in human are somewhat different from those in mouse. In fact, mouse hepatoblasts do not express CK19, whereas human hepatoblasts are known to express CK19 (Stosiek et al., 1990 ).
In conclusion, we showed that mouse hepatoblasts exhibit a transient expression of EpCAM during liver development and that the combination of DLK1 and EpCAM expression provided evidence for the developmental pathways of mouse liver precursor cells. Defining cell lineages and differentiation stages is a critical step to understand the mechanism of organogenesis. We showed that the earliest mouse hepatoblasts could be identified and isolated prospectively by the expression of EpCAM as early as E11.5. Further investigation on the profile of cell-surface markers will help us to isolate a specific type of precursor cells and to understand mechanisms of each cell differentiation.
3.
Materials and methods
Mice
C57BL/6 mice (Nihon SLC, Hamamatsu, Japan) were used for all experiments. All experiments with animals were performed according to institutional guidelines.
Antibodies
Anti-DLK1 (24-11) monoclonal antibody (mAb) and 40-1 mAb recognizing hepatoblasts were generated by immunization of a rat with E14.5 mouse fetal liver cells deprived of hematopoietic cells, and screened as previously reported (Suzuki et al., 2008) . The anti-DLK1 mAb is commercially available from MBL International (Woburn, MA). The anti-EpCAM mAbs were generated by immunization of a rat with Ba/F3 transfectants expressing mouse EpCAM cDNA (Okabe et al., 2009) . Hybridomas expressing mAb were established by fusion of lymphocytes and P3X myeloma cells with polyethyleneglycol as described previously (Hara et al., 1999 fectants constitutively expressing mouse EpCAM. Each mAb against DLK1, EpCAM and 40-1 was FITC-labeled or biotinylated and used for FCM. The rabbit anti-mouse CK19 polyclonal Ab was raised against the C-terminal peptide, HYNNLPTPKAI, and the serum was used for immunostaining, as previously described (Tanimizu et al., 2003) . Rhodamine Dolichos biflorus agglutinin was purchased from Vector Labolatories (Burlingame, CA). Anti-HNF4a Ab (H-171) (Santa Cruz Biotechnology) and anti-mouse CD326 (EpCAM) (G8.8) (BD Pharmingen) were used for IHC.
Immunohistochemistry
Whole embryos or fetal liver were fixed by incubation in a 4% paraformaldehyde solution at 4°C overnight, followed by dehydration sequentially in 15% sucrose and 30% sucrose solution overnight, and then embedded in OCT. Cryostat sections (7 lm) were incubated with each Ab, followed by a biotin-or fluorescein-conjugated secondary Ab. The signals were visualized using the Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA) or fluorescence microscopy. Primary Abs used were: anti-EpCAM 1:200 (BD Pharmingen, San Diego, CA); anti-DLK1 1:200 (MBL); anti-CK19 1:1000. Secondary Abs used were conjugated to FITC or PE (BD Pharmingen).
Preparation and isolation of liver cells
Fetal liver cells were prepared according to the method of Kamiya et al. (1999) These cells were used for FCM analysis and isolation of EpCAM + cells. EpCAM + cells were isolated using AutoMACS according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, E11.5 liver cells were incubated with anti-FcR Ab for the block of FcR, and then incubated with FITC-conjugated anti-EpCAM mAb. After washing with phosphate-buffered saline (PBS), cells were resuspended in AutoMACS running buffer, and 100 ll/ml of anti-FITC-labeled microbeads (Miltenyi Biotec) were added. After washing with the running buffer, the cells were loaded onto a magnetic column and EpCAM + cells were eluted from the column after the depletion of EpCAM À cells. 
Colony formation assay
Fetal liver cells were cultured as previously described (Tanimizu et al., 2003) . Briefly, cells were plated at 50 cells/cm 2 in DMEM/F12 medium supplemented with10% FBS, 1· ITS, 10 mM nicotineamide (Wako, Tokyo, Japan), 0.1 mM dexamethasone, 5 mM L-glutamine, 20 ng/ml EGF (PeproTech, London, UK), and 20 ng/ml HGF (R&D, Minneapolis, MN) on a type I collagen-coated dish. After 6 days of culture, the number of colonies was determined.
RNA extraction and reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted from each cell preparation with Trizol reagent (Invitrogen, Carlsbad, CA). Total RNA and random hexamer primers were used to synthesize cDNA using the First-strand cDNA synthesis kit (Amersham Pharmacia Biotech, Piscataway, NJ). The PCR primers and conditions are described below: the samples were denatured at 95°C for 20 s, followed by 30-40 thermal cycles; denaturation at 95°C for 10 s, annealing at 56°C for 20 s, and extension at 72°C for 90 s, with a final extension at 72°C for 5 min. PCR primers of albumin, AFP, HNF4a, CK19 were described previously (Tanimizu et al., 2003) . 
